InvestorsHub Logo
Followers 4
Posts 479
Boards Moderated 0
Alias Born 01/03/2015

Re: None

Saturday, 09/08/2018 2:04:49 PM

Saturday, September 08, 2018 2:04:49 PM

Post# of 403036
Looking forward to seeing the dose dependant improving response of P using 2x the dose as P2a study. Twice the dose and easier trial conditions. Also, secondary endpoint analysis should be interesting as the company was aiming to be understand other potential applications of Prurisol.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News